Korea South
MxT Biotech, founded in 2021, is a promising startup emerging from a Korea University spin-out, establishing itself within the Biotechnology and Health Care industries. This South Korea-based company is dedicated to the development of innovative microfluidic platforms that aim to revolutionize cell engineering and immunotherapies.
Operating under the slogan "Developing transformative microfluidic platforms for cell engineering and immunotherapies," MxT Biotech focuses primarily on pioneering microfluidic gene delivery systems to advance Cell and Gene Therapy (CGT). Despite its recent inception, the startup has not yet disclosed any external investments or investor participation.
In summary, MxT Biotech presents a compelling investment opportunity by aligning advanced microfluidics with therapeutic innovations, positioning itself favorably in a sector that continuously seeks breakthrough technologies for disease treatment and management.